KRAS and lung carcinoma: Synergism between MEK and FGFR inhibition has previously been established in the context of KRAS mutant lung cancer: a shRNA screen of Tra-treated H23 KRASG12C lung cancer cells identified FGFR1 signaling as compensatory for MEK inhibition33.